The neuroscience facility employs a multidisciplinary systems approach to elucidate the underlying mechanisms of acute and chronic neurological diseases. This involves using in vitro models, Drosophila, and animal models (mice and rats). The in vitro oxygen-glucose deprivation (OGD) model is employed to simulate pre-clinical ischemic stroke conditions and also Alzheimer’s and Parkinson’s disease cell model. Additionally, the facility utilizes transgenic tools to study human Alzheimer's disease (AD), Parkinson's disease (PD), and epilepsy in Drosophila.The laboratory is well-equipped for behavioural, histochemical, and molecular analyses in Drosophila. A major focus of the facility is to understand the role of gut microbiomes in the development of neurological diseases. Furthermore, the facility is dedicated to screening phytochemicals and novel drugs for their potential in mitigating Alzheimer’s, Parkinson’s, ischemic stroke, and epilepsy.
